Publications by authors named "Ting-Wa Lam"
Background & Aims: The Chinese herbal medicine, MaZiRenWan (MZRW), has been used for more than 2000 years to treat constipation, but it has not been tested in a randomized controlled trial. We performed a trial to evaluate the efficacy and safety of MZRW, compared with the stimulant laxative senna or placebo, for patients with functional constipation (FC).
Methods: We performed a double-blind, double-dummy, trial of 291 patients with FC based on Rome III criteria, seen at 8 clinics in Hong Kong from June 2013 through August 2015.
Background And Aim: Transarterial radioembolization with yttrium-90 microspheres is one treatment option for inoperable hepatocellular carcinoma. We compared the survival in a cohort of patients receiving radioembolization or no radioembolization.
Methods: The data of 46 patients referred for radioembolization was retrospectively reviewed.
Article Synopsis
- Functional constipation is common, and a study suggests that Ma Zi Ren Wan, a Chinese herbal remedy, shows promise but requires more evidence compared to conventional Western treatments.
- The research will involve a double-blinded, randomized controlled trial with participants assigned to one of three groups: Ma Zi Ren Wan, senna (a laxative), or placebo over 16 weeks.
- This is the first trial to directly compare Chinese herbal medicine with a Western laxative, aiming to determine the effectiveness of Ma Zi Ren Wan and provide clinical recommendations.
Background/aims: Exposure to HBV leads to a distinct clinical course which is partially pertained to host genetic variability. We aimed to study polymorphisms of type I interferon receptor 1 (IFNAR1) promoter and their potential effects on chronic HBV infection.
Methods: Polymorphisms of IFNAR1 promoter were identified in 320 chronic hepatitis B patients, 148 spontaneously recovered individuals, 148 healthy Chinese donors and 114 Caucasians.
Background And Aim: Adjuvant locoregional chemotherapy has been shown to be useful to prevent recurrence after curative resection of hepatocellular carcinoma (HCC) in some retrospective studies. Our aim was to compare the dose effect in the prevention of tumor recurrence.
Methods: A prospective randomized controlled trial was conducted in patients with curative resection of HCC; they were given either one intra-arterial dose of cisplatin/lipiodol, or received four doses, once every 3 months.